TOP 5 PRIORITY STOCKS
Tip: Use buttons in top-right corner to sort by gain or reset
$189.39
BUY
Entry:
$188.00 - $190.00
Stop Loss:
$172.00
TP1: $195.00
+3.5%
TP2: $212.19
+12.0%
TP3: $253.88
+34.1%
Risk/Reward: 1:3.5
🎯 Earnings: February 25, 2026
✅ Complete Analysis
$362.26
BUY
Entry:
$360.00 - $365.00
Stop Loss:
$343.58
TP1: $374.52
+3.4%
TP2: $380.00
+4.9%
TP3: $400.00
+10.4%
Risk/Reward: 1:2.5
🎯 3nm capacity fully booked through 2026
✅ Complete Analysis
$17.73
BUY
Entry:
$17.50 - $18.00
Stop Loss:
$16.40
TP1: $22.00
+24.1%
TP2: $25.00
+41.0%
Risk/Reward: 1:4.0
🎯 VW partnership ($5.8B JV), R2 SUV launch Q2 2026
✅ Complete Analysis
$14.12
BUY
Entry:
$14.00 - $14.20
Stop Loss:
$13.50
TP1: $15.50
+9.8%
TP2: $16.00
+13.3%
Risk/Reward: 1:2.0
💰 Dividend: 4.25% yield
✅ Complete Analysis
$1,019.11
STRONG BUY
Entry:
$1,010.00 - $1,025.00
Stop Loss:
$980.00
TP1: $1,170.00
+14.8%
TP2: $1,250.00
+22.6%
Risk/Reward: 1:4.0
🎯 FDA decisions (orforglipron, retatrutide) Q1 2026
✅ Complete Analysis
MARKET CONTEXT
Current Phase: Pullback - Minervini strategy working better than Dan Zanger
Recommendation: ORB (Opening Range Breakout) for day trading
Sector Strength:
Semiconductors: TSM, NVDA
Auto: RIVN, F, GM, LI, NIO
Pharma: LLY, GILD, MAIRE
Retail: LOW, WMT, HD, TGT, COST
Crypto: COIN
Important Catalysts:
1
February 25: NVDA earnings, LOW earnings
2
March 10: MAIRE earnings
3
Q1 2026: LLY FDA decisions (orforglipron)
4
Q2 2026: RIVN R2 SUV launch
EXECUTION PLAN
Priority 1 (Buy this week):
1
NVDA - before earnings February 25
2
TSM - strong momentum
3
RIVN - VW partnership catalyst
Priority 2 (Buy on pullback):
4
F - cheap valuation, dividend
5
LLY - strong FDA catalysts
Priority 3 (Monitor):
6
TXN - wait for entry below $215
7
COIN - high risk/high reward
RISK MANAGEMENT STRATEGY
Position Sizing
Core Positions:
20-25% per stock
Secondary:
10-15% per stock
Diversification:
Max 5-7 stocks
Stop Loss Levels
Technical support:
3-5% below entry
Moving averages:
50/200-day MA
Volume-based:
Break below support
Take Profit Levels
TP1:
Nearest resistance (3-7%)
TP2:
52-week high (10-15%)
TP3:
Analyst target (20%+)
DISCLAIMER
This report is for informational purposes only and should not be considered investment advice. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.
Produced by: OAK AI
Date: February 19, 2026
Analysis based on: Minervini Scanner, Dan Zanger Scanner, Multi-agent analysis pipeline
📚 DEEP-DIVE ANALYSIS AVAILABLE
🔗 Complete Stock Analysis Reports
For stocks marked with 🔗, detailed analysis reports are available for purchase. Each report includes:
- Comprehensive technical analysis with entry/exit levels
- Fundamental valuation metrics and financial health assessment
- Risk management framework with stop-loss and take-profit targets
- Market context and sector analysis
- Catalyst timeline for upcoming events
🌐 Complete Analysis on OAK AI
📊 View All Analysis Reports on Gumroad
Click the link icon (🔗) next to any stock to view its specific analysis